Synergistic Effects of MAPK and Immune Checkpoint Inhibitors in Melanoma: what is the Best Combination Strategy?

James S. Wilmott; Peter Hersey; Georgina V. Long; Richard A Scolyer

doi:10.2217/mmt.14.26

Related publications

Article2025

Abstract LB320: Broad and synergistic anti-tumor effects of small-molecule dual HIF-1/2 inhibitors in combination with immune checkpoint inhibitors

Shaima Salman, Tina Huang, Yousang Hwang, Anmol Kumar, Alexander D. MacKerell, Gregg L. Friedman

Article2020

Efficacy of immune checkpoint inhibitors for in-transit melanoma

Georgina V. Long, Grant A. McArthur, Shahneen Sandhu, Robyn P.M. Saw, Euan Walpole, Alexander M. Menzies, B. Mark Smithers, David Gyorki, Emilia Nan Tie, Julia Lai‐Kwon, Michael Rtshiladze, Lumine Na, J Bozzi, Tavis Read, Victoria Atkinson, George Au‐Yeung

Article2019

Efficacy of immune checkpoint inhibitors (ICIs) for in-transit melanoma.

Emilia Nan Tie, Julia Elizabeth Lai-Kwon, Lumine Na, Michael Rtshiladze, J Bozzi, Tavis Read, Victoria Atkinson, George Au‐Yeung, Georgina V. Long, Grant A. McArthur, Shahneen Sandhu, Robyn P.M. Saw, Euan Walpole, Alexander M. Menzies, B. Mark Smithers, David Gyorki

Article2017

PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors

Hojabr Kakavand, Robert V. Rawson, Gulietta M. Pupo, Jean Yang, Alexander M. Menzies, Matteo S. Carlino, Richard Kefford, Julie R. Howle, Robyn P.M. Saw, John F. Thompson, James S. Wilmott, Georgina V. Long, Richard A Scolyer, Helen Rizos

Article2017

Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma

Tuba N. Gide, James S. Wilmott, Richard A Scolyer, Georgina V. Long